Although most pediatric syncope cases are benign, general providers should be able to distinguish red-flag symptoms and refer patients as necessary. “Providers should differentiate syncope from cardiac conditions, seizures, metabolic disturbances or psychogenic causes,” said Delwyn E. McOmber, M.D., pediatric cardiologist with Norton Children’s Heart Institute, affiliated with the UofL School of Medicine. By taking…
Hydrocephalus in newborns represents one of the most challenging conditions faced in neonatal care. Early recognition and appropriate intervention are crucial for optimal outcomes. The key to managing newborn hydrocephalus lies in recognizing changes over time. “It’s not what the brain looks like at any moment. It’s what it looks like today versus previously,”…
Neonatal seizures represent one of the most common and challenging neurologic conditions encountered in the neonatal intensive care unit. The unique characteristics of the developing nervous system and their often subtle clinical manifestations complicate recognition and management, according to Lester M. “Max” Gallivan, M.D., a resident in pediatric neurology at the UofL School of Medicine and…
Neonatal hypotonia, or “floppy infant syndrome,” is a common condition encountered after delivery and in the neonatal intensive care unit (NICU). Early diagnosis and differentiating etiology of low tone are critical to help prevent further complications. “Hypotonia can be a manifestation of systemic illness or dysfunction of any level of the nervous system,” said Amanda…
Norton Neuroscience Institute is one of six sites nationwide chosen to pilot a new Brain Health Navigator program aimed at creating a worldwide model to prevent, diagnose and treat Alzheimer’s disease. The program — funded and pioneered by the Davos Alzheimer’s Collaborative — provides resources for patients and providers at these six sites. “This collaborative effort continues…
A recent study published in the The Journal of Prevention of Alzheimer’s Disease provides detailed insight into clinicians’ and patients’ initial experience with lecanemab, the first Food and Drug Administration-approved antiamyloid monoclonal antibody infusion proven to slow cognitive and functional decline due to Alzheimer’s disease. Conducted at the Norton Neuroscience Institute Memory Center, the study…
Cerebral palsy describes a range of permanent motor function disorders arising from a one-time change to the fetal or infant brain. Cerebral palsy symptoms are secondary to a brain injury or malformation before, during or shortly after birth, according to Christopher R. Barton, M.D., a pediatric neurologist with Norton Children’s Neuroscience Institute, affiliated with the…
David A. Robertson, M.D., neurologist and neuroimmunologist, has joined Norton Neuroscience Institute Hussung Family Multiple Sclerosis Center. Dr. Robertson is originally from McPherson, Kansas. He graduated from the University of Kansas School of Medicine in 2004 and completed an internship in internal medicine and a residency in neurology, both at Vanderbilt University in Nashville, Tennessee. As a…
Norton Neuroscience Institute will be the first and only facility in Kentucky to offer MRI-guided high-frequency focused ultrasound for essential tremor and tremor-dominant Parkinson’s disease. This life-changing treatment has been shown to dramatically improve tremor symptoms for patients starting on the day of treatment. The technology will be purchased with $2.8 million in funding through the Norton Healthcare Foundation. High-frequency…
A study showed that about 45% of dementias are preventable through lifestyle modifications. The societal impacts of this research include reducing financial burdens on the health care system, improving social participation and population health, and improving quality of life for millions of Americans. “Primary care clinicians can now start the conversation about cognitive health with…
New monoclonal antibody therapies targeting beta-amyloid deposition in the brain have shown success in slowing the progression of Alzheimer’s disease, though the risk of serious side effects necessitates careful evaluation and discussion before initiating treatment.. In January 2023, the Food and Drug Administration (FDA) gave accelerated approval to lecanemab, which goes by the brand name…
Neuromuscular disorders are conditions that affect the structure and function of the peripheral nervous system, as well as all motor and sensory nerves. The predominant symptom of this group of disorders is progressive muscle weakness. Secondary symptoms may include muscular atrophy and disturbances in sensation, which may present as tingling or numbness. The developments in…